Dr Sumit Subudhi speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about initial results from the CheckMate 650 study looking at nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer.

He reports that the combination of treatment can lead to some very promising results, with two patients in his own institution showing PSA levels of 0 and no sign of disease after 1.5 years.

Dr Subudhi acknowledges that not all patients have benefited and that biomarkers, such as the tumour mutational burden, need to be further evaluated to predict which patients will respond.

Read more about this work here.